News Pfizer promotes potential CEO successor Bourla Move could allow CEO Read to focus on mega-merger.
GlaxoSmithKline GSK's new CEO Walmsley paid 25% less than predecessor Witty GlaxoSmithKline (GSK) has confirmed rumours that its incoming CEO Emma Walmsley will be paid less than her predecessor, Sir Andrew Witty.
GlaxoSmithKline GSK under pressure to rein in new CEO pay Emma Walmsley's deal under scrutiny amid crackdown on boardroom pay.
News Third death reported with a Sarepta gene therapy A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
